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Introduction: Intrinsic or acquired chemoresistance is a major problem in oncology. Although highly responsive to
chemotherapies such as paclitaxel, most triple negative breast cancer (TNBC) patients develop chemoresistance. Here
we investigate the role of BRCA1-IRIS as a novel treatment target for TNBCs and their paclitaxel-resistant recurrences.
Methods: We analyzed the response of BRCA1-IRIS overexpressing normal mammary cells or established TNBC cells
silenced from BRCA1-IRIS to paclitaxel in vitro and in vivo. We analyzed BRCA1-IRIS downstream signaling pathways in
relation to paclitaxel treatment. We also analyzed a large cohort of breast tumor samples for BRCA1-IRIS, Forkhead box
class O3a (FOXO3a) and survivin expression. Finally, we analyzed the effect of BRCA1-IRIS silencing or inactivation on
TNBCs formation, maintenance and response to paclitaxel in an orthotopic model.
Results: We show that low concentrations of paclitaxel triggers BRCA1-IRIS expression in vitro and in vivo, and that
BRCA1-IRIS activates two autocrine signaling loops (epidermal growth factor (EGF)/EGF receptor 1 (EGFR)-EGF receptor
2 (ErbB2) and neurogulin 1 (NRG1)/ErbB2-EGF receptor 3 (ErbB3), which enhances protein kinase B (AKT) and thus
survivin expression/activation through promoting FOXO3a degradation. This signaling pathway is intact in TNBCs
endogenously overexpressing BRCA1-IRIS. These events trigger the intrinsic and acquired paclitaxel resistance phenotype
known for BRCA1-IRIS-overexpressing TNBCs. Inactivating BRCA1-IRIS signaling using a novel inhibitory mimetic peptide
inactivates these autocrine loops, AKT and survivin activity/expression, in part by restoring FOXO3a expression, and
sensitizes TNBC cells to low paclitaxel concentrations in vitro and in vivo. Finally, we show BRCA1-IRIS and survivin
overexpression is correlated with lack of FOXO3a expression in a large cohort of primary tumor samples, and that
BRCA1-IRIS overexpression-induced signature is associated with decreased disease free survival in heavily treated
estrogen receptor alpha-negative patients.
Conclusions: In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired
paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3. These loops
activate AKT, causing FOXO3a degradation and survivin overexpression. Taken together, this underscores the need for
BRCA1-IRIS-specific therapy and strongly suggests that BRCA1-IRIS and/or signaling loops activated by it could be rational
therapeutic targets for advanced TNBCs.Introduction
Paclitaxel is a powerful chemotherapy for many cancers,
such as breast, prostate and ovarian cancers [1-5], as
well as chemotherapy-refractory cancers such as small
cell lung cancer [6-8]. Paclitaxel polymerizes tubulin to
disrupt normal microtubule dynamics leading to cell death
[4]. Despite preclinical and clinical success, intrinsic or* Correspondence: welshamy@umc.edu
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oncology [9-12].
Survivin, a structurally unique member of the inhibitor
of apoptosis proteins family (IAP) is involved in cell
division and apoptosis [13-15]. Survivin is a poor
prognostic factor in several tumor types, and is
involved in tumor cell resistance to ionizing radiation
and chemotherapies for example, paclitaxel [16-20]. In
fact, survivin expression is induced following paclitaxel
exposure in breast cancer cells [21,22]. Survivin
expression is negatively controlled by the Forkhead
box class O (FOXO) transcription activity [23,24] andral. This is an Open Access article distributed under the terms of the Creative
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kinase B (AKT) [24-27].
FOXO proteins play a pivotal role in the regulation of
cell cycle arrest, cell death and protection from stress
stimuli [23]. Perturbation of FOXO’s function deregulates
cell proliferation and leads to accumulation of DNA
damage [23,25]. AKT, or mitogen-activated protein kinases
(MAPK), phosphorylate FOXOs at specific sites, causing
its nuclear exclusion and degradation [23,26]. Constitutive
AKT activation is frequently correlated with cytoplasmic
Forkhead box O3a (FOXO3a) and decreased patient sur-
vival in breast cancer and other malignancies [25,27,28].
Drugs like paclitaxel achieve their therapeutic effects
through activation of FOXO3a [29-31].
Triple negative breast cancer (TNBC) is an aggressive
breast cancer subtype lacking estrogen receptor (ER)
and progesterone receptor (PR) expression and human
epidermal growth factor receptor 2 (HER2) gene amplifi-
cation. Hence, patients with this subtype lack targeted
therapies. TNBC constitutes approximately 20% of all
breast cancers in the USA and is overrepresented in
young African American women. TNBC tumors have
the poorest prognosis and tend to grow and spread to
other parts faster than other cancers and often harbor
BRCA1 mutations or lack of expression. Although,
initially responsive to paclitaxel, TNBCs often recur with
chemotherapy-resistant, visceral and brain metastasis.
The BRCA1 locus product, BRCA1-IRIS, shares 1,365
residues with the full-length product of this locus, the
tumor suppressor, BRCA1 [32,33]. Despite that, BRCA1-IRIS
is a genuine oncogene in breast and ovarian cancers. Indeed,
BRCA1-IRIS overexpression induces over-replication [32],
over-proliferation by upregulating Cyclin D1 expression
[34,35], apoptosis-resistance in human mammary (HME)
and ovarian surface (HOSE) epithelial cells by inactivating
p53 and/or activating AKT/survivin [36,37]. The majority of
breast tumors, especially TNBCs express high levels of
BRCA1-IRIS associated with increased p-AKT and survivin
expression, and lack of BRCA1 expression [38]. Interestingly,
BRCA1-IRIS-overexpressing HME cells when injected
in SCID mice mammary fat pads develop invasive TNBCs
that also show increased AKT and survivin expression
and/or activation and lack BRCA1 expression [38].
Understanding the various mechanisms leading to
paclitaxel resistance may help in the design of novel, more
accurate therapies [12]. Here, we show BRCA1-IRIS over-
expression is involved in TNBCs intrinsic and acquired
paclitaxel resistance, through, in part, increasing expression
and activation of autocrine signaling loops involving
epidermal growth factor receptor 1 (EGFR) and epidermal
growth factor receptor 3 (ErbB3) that activate AKT leading
to FOXO3a degradation and survivin overexpression.
BRCA1-IRIS inactivation using a novel inhibitory mimetic
peptide reversed these effects and significantly reducedTNBC cells growth, survival and aggressiveness, in vitro
and in vivo. More importantly, this peptide sensitized
established preclinical TNBCs to low paclitaxel concentra-
tions. BRCA1-IRIS inactivation represents a novel and
attractive target for TNBCs.
Methods
Cell culture
Generation and maintenance of the immortalized
HME cells and its variants, BRCA1-IRIS-overexpressing
(HME/IRIS) cell lines, were described earlier [32,36]. In
brief, immortalized HME cells were generated from
mammary epithelial cells purified from tissues isolated
from mammary gland reductions (Clontech Laboratories,
Mountain View, CA, USA) using standard techniques
by a suitable human telomerase reverse transcriptase
(TERT)-expressing virus and selection [32]. Full-length
BRCA1-IRIS cDNA was cloned into the pRevTRE plasmid
(retrovirus version, Clontech Laboratories) to produce
the pRevTRE-IRIS retrovirus. Retroviral particles were
generated by transfecting 293T cells with pRevTRE-IRIS
together with all necessary packaging plasmids. On days 2
and 3 viral supernatant was collected, pooled, and used as
is to infect immortalized HME cells stably expressing
p-TetOn plasmids (Clontech Laboratories, with suitable
selection). Infected cells were then selected using hygromy-
cine for 2 weeks, and 10 to 15 clones were generated, all
referred to HME/IRIS. Ectopic BRCA1-IRIS expression in
these clones is induced by exposure to 2 μg/ml of doxycyc-
line (Invitrogen, Carlsbad, CA, USA). BRCA1-IRIS was
verified at the beginning and periodically using western blot
using mouse anti-human BRCA1-IRIS-specific antibody.
While variation between clones exists, in every clone the
expression is approximately two- to fivefold above the level
in normal immortalized HME cells and resembling that
found endogenously expressed in TNBC cell lines. Other
cell lines, such as MDA-MB-231 (HTB-26), MDA-MB-468
(HTB-132) and BT-549 (HTB-122) cell lines were
from American Type Culture Collection (ATCC) and were
maintained in RPMI 1640 medium containing 10% fetal
bovine serum (FBS). All cell lines used in this study were
transfected with a retrovirus expressing the luciferase gene.
Antibodies
Rb anti-survivin (#2808), −EGF (ab9695), −EGFR (ab23430),
−p-ErbB2 (ab131104), −ErbB3 (ab20161), −FOXO3a
(ab47409), −FOXO1 (ab39670), and -p-FOXO (T32,
ab26649), or m anti-p-EGFR (Y1173; ab24912), −H2B
(ab52484) and -PCNA (ab18197) were from Abcam
(Cambridge, MA, USA). Rb anti-ErbB2 (#2165), −Cyclin
D1 (#2978), −PTEN (#9188), −AKT (#2938), −p-AKT
(S463, #4060), −ERK (#4695), −p-ERK (T202/Y204,
#4370), −JNK (#9258), −p-JNK (T183/Y185, #9255), −p38
(#8690), −p-p38 (T180/Y182, #2387), −Bcl2 (#2870), −Bcl-xL
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Technology (Danvers, MA, USA). The m anti-NRG1
(MAB377) was from R&D Systems (Minneapolis, MN,
USA). The m anti-nuclear factor kappa B (NF-κB)/
p65 (IMG-150A) was from Imgenex (San Diego, CA,
USA), the Rb anti-MDM2 (s1357) was from Epitomics
(Burlingame, CA, USA) and the m anti-actin (cp01)
was from Calbiochem (San Diego, CA, USA). Mouse
monoclonal anti-human anti-BRCA1-IRIS was developed
in our laboratory.
Small interfering RNA transfections, and small hairpin
RNA construction and generation of stable knockdown
cell lines
Small interfering RNA (siRNA) transfections and
protocol were described previously [32]. BRCA1-IRIS
small hairpin RNA (shRNA) was designed using the
‘shRNA Design Tool’ from the IDT website [39], (sequence
available upon request), inserted between BamHI and
EcoR1 sites in pSIREN-RetroQ plasmid (Addgene,
Cambridge, MA, USA).
Immunohistochemistry (IHC) staining and scoring
Breast tissue microarrays comprised of normal, ductal
carcinoma in situ (DCIS), invasive and metastatic
samples were purchased from US Biomax, Inc. (Rockville,
MD, USA). IHC protocols were described earlier [38]. A
semi-quantitative scoring system was used to identify the
percentage of tumor cells showing positive staining [40].
Scoring represents: overall stain intensity and percentage
of cancer cells stained in four high magnification fields for
each sample. Average overall staining intensity [41] was
valued as percentage of cell stained/field: zero (<1%
staining) was considered negative; 1 (1 to 10% staining)
was considered weakly stained; 2 (10% to 50% staining)
was considered medium stained and 3 (>50% staining) was
considered strongly stained. The positive staining scoring
method is totally subjective and artifacts such as high
background or variable stain deposition can skew the
results and the scores for the two categories remain
as separate functions and cannot be combined for
analysis and comparison [42].
In vivo tumorigenicity assay
All animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) of the
University of Mississippi Medical Center. SCID (Jackson
Laboratory, Bar Harbor, ME, USA) or Nu/Nu (Harlan
Laboratories, Indianapolis, IN, USA) female mice were
used. Protocols were previously described [38].
BRCA1-IRIS inhibitory peptide
A synthetic peptide corresponding to amino acids
1365–1399 of BRCA1-IRIS protein (see [32] for sequence)conjugated to cell and nuclear penetrating sequence
was used.Cell viability measurement
Cell viability under different experimental conditions
was determined using cell counting or MTS assay.Cell migration assay
μ-Dish (35mm, high Culture-Inserts, ibidi GmbH,
Munich, Germany) was used. Inserts surrounded control
or BRCA1-IRIS shRNA MDA-MB-231 or MDA-MB-468-
expressing cells until confluence. At which time, inserts
were removed, floating cells washed and attached cells
allowed to migrate for 24 h. A montage of multiple
pictures representing the whole well was mounted
digitally together and migration calculated from a
fixed point. Each experiment was done in triplicate
repeated three separate times.Cell invasion assay
Growth factor-reduced BD matrigel™ invasion chambers
(24-well plate, 8.0μm, BD BioCoat™) were used (BD
Biosciences, San Jose, CA, USA). Invaded cells were
Crystal Violet stained 7 days later, photographed and
counted. Each experiment was done in triplicate repeated
three separate times.Mammosphere assay
Ultra-low attachment 6-well plates (Corning Life Sciences,
Union City, CA, USA) were used. Every third day,
medium was exchanged with one containing treatments
for up to 10 days when mammospheres were counted and
photographed. Each experiment was done in triplicate
repeated three separate times.In vivo efficacy of BRCA1-IRIS inhibitory peptide
Female Nu/Nu mice (6 to 8 weeks old) were injected
with 2 x 106 of MDA-MB-468 cells in the second
right and fourth left mammary gland. Mice bearing
tumors of approximately 100 mm3 were randomly grouped
to receive DMSO (intraperitoneally (i.p.)) + scrambled
peptide (10 mg/kg) intratumorally (i.t.), IRIS peptide
(10 mg/kg, i.t.), paclitaxel (10 mg/kg, i.p.), or IRIS
peptide (5 mg/kg, i.t.) + Taxol (5 mg/kg, i.p.) every
third day for four times per experiment. Tumor volume
was measured by caliper and is represented as per-
centage of volume at day 0 of treatment. At the end
point, tumors or their remnants were collected, fixed in
10% formalin and histologically or immunohistochemically
analyzed.
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BRCA-IRIS overexpression triggers paclitaxel resistance,
in vitro
We recently showed BRCA1-IRIS overexpression promotes
intrinsic as well as acquired cisplatin resistance in ovarian
tumor and HOSE cells, respectively [37]. We also showed
that BRCA1-IRIS silencing or inactivation using a novel
inhibitory peptide reversed both [37]. Thus, we hypothesized
that BRCA1-IRIS overexpression could also be involved in
paclitaxel resistance developed in TNBC patients [4,9].
To study BRCA1-IRIS overexpression on the intrinsic
or acquired paclitaxel resistance, HME/IRIS and three
TNBC cell lines; MDA-MB-231, MDA-MB-468 and
BT549 or HME cells were used. All cell lines were
exposed to increasing concentrations of paclitaxel and
cells viability and BRCA1-IRIS expression were measured.
HME cells were the most sensitive cell line, showing an
IC50 of approximately 5 μM (black line in Figure 1A, left).
MDA-MB-468 cells were the most sensitive TNBC cell
line [43], showing an IC50 of approximately 20 μM
(orange line in Figure 1A, left), whereas BT549 and
MDA-MB-231 were more resistant showing IC50 of
approximately 35 μM (blue line in Figure 1A, left)
and >50 μM (green line in Figure 1A, left), respectively.
Interestingly, HME/IRIS cells were as resistant as
MDA-MB-231 cells showing an IC50 of approximately
50 μM (red line in Figure 1A, left). Moreover, resistance
level was well correlated with BRCA1-IRIS expression in
each cell line. Cell lines showing high basal level of
BRCA1-IRIS and maintaining a high level after treatment,
such as BT549, HME/IRIS and MDA-MB-231, were more
resistant than those that had high basal of BRCA1-IRIS
but failed to maintain a high level after treatment,
such as MDA-MB-468 (see inset in Figure 1A, left).
Taken together, these data suggest a direct relationship
between the level of BRCA1-IRIS and the intrinsic
paclitaxel resistance in TNBC cells.
Direct role for BRCA1-IRIS overexpression in TNBC cells
paclitaxel resistance
To show the direct role of BRCA1-IRIS overexpression
in TNBC cells paclitaxel intrinsic resistance, MDA-MB-231,
MDA-MB-468 and BT549 cells were transfected with
luciferase (siLuc, negative control) or BRCA1-IRIS
(siIRIS)-specific siRNAs for 48 h before they were exposed
to increasing concentration of paclitaxel and survival was
measured by cell counting 24 h later. Alternatively,
silenced cells were treated with 5 μM of paclitaxel
and proteins isolated 24 h later were interrogated by
western blot analysis.
Compared to siLuc-transfected cells, BRCA1-IRIS-
silenced cells survival was significantly decreased when
treated with paclitaxel. Indeed, in the more resistant
TNBC cell lines, BT-459 or MDA-MB231, IC50 droppedfrom ≥50 μM (light blue and green line, respectively
Figure 1A, right) to approximately 10 μM (dark blue
and green line, respectively Figure 1A, right) when
BRCA1-IRIS was silenced in them. Moreover, even
the more sensitive MDA-MB-468 cells became more
sensitized and the IC50 dropped from approximately
20 μM (light-brown line, Figure 1A, right) to 5 μM
when BRCA1-IRIS was silenced in them (dark-brown
line, Figure 1A, right).
On the molecular level, compared to vehicle-treated
cells, paclitaxel treatment induced BRCA1-IRIS, p-AKT,
p-FOXO, survivin and Cyclin D1 in MDA-MB-468 cells
(compare siLuc on the right to the left in Figure 1B). In
the absence of BRCA1-IRIS, this induction as well as the
basal level of these survival factors was significantly
decreased (compare siIRIS on the right and the left in
Figure 1B). Taken together, these data clearly show that
some if not all paclitaxel-intrinsic resistance in TNBC
cells depends on BRCA1-IRIS overexpression.
Signaling loops involved in BRCA1-IRIS-induced intrinsic
and acquired paclitaxel resistance
Although, HME cells were the least resistant to paclitaxel
(Figure 1A, left), BRCA1-IRIS expression increased in
them following paclitaxel treatment, especially at lower
concentrations (inset in Figure 1A, left). This made us
wonder whether in vivo too naïve HME cells exposed to
low paclitaxel concentrations respond by upregulating
BRCA1-IRIS expression in order to survive. Now genetically
altered and BRCA1-IRIS overexpressing, these cells could
pose an imminent risk later if they survived and grow as a
paclitaxel-resistant TNBC clone.
Thus, to define on the molecular level the role of
BRCA1-IRIS in paclitaxel-acquired and intrinsic resistance,
we analyzed HME and HME/IRIS cells exposed to 0, 10,
20 or 30 μM of paclitaxel for 24 h. Paclitaxel-acquired
increase in BRCA1-IRIS, EGFR and ErbB3 (not epidermal
growth factor receptor 2 (ErbB2)), epidermal growth factor
(EGF) and neurogulin 1 (NRG1) expression in HME cells
was documented (Figure 1C, left). All were intrinsically
high in HME/IRIS and remained unchanged after
treatment (Figure 1C, left). In keeping with that, a
paclitaxel-acquired increase in EGFR activation detected
as an increase in p-Y1173-EGFR, which is induced by EGF
binding to the EGFR-ErbB2 complex and ErbB2 activation
detected as increase in p-Y1248-ErbB2, which is induced by
NRG1 binding to the ErbB2-ErbB3 complex in HME cells,
were detected (Figure 1C, left). Both were intrinsically
high in HME/IRIS cells and remained unchanged after
treatment (Figure 1C, left).
Furthermore, a paclitaxel-acquired decrease in
PTEN level in HME cells, while intrinsically low in
HME/IRIS cells, remained unchanged after drug treat-
ment was documented (Figure 1C, right). Concurrently, a
Figure 1 BRCA1-IRIS overexpression promotes intrinsic and acquired paclitaxel resistance in TNBC cells. (A) The survival of HME, HME/IRIS
and the indicated TNBC cell lines following treatment with increasing concentrations of paclitaxel. Values are means of triplicates done three
separate times. Inset shows BRCA1-IRIS expression in these cell lines following exposure to increasing concentrations of paclitaxel. (B) The expression
of the indicated proteins following treatment with vehicle or paclitaxel (5 μM) for 24 h or MDA-MB-468 previously silenced from luciferase or
BRCA1-IRIS for 48 h. (C) The expression of the indicated proteins in HME or HME/IRIS cells following exposure to 0, 10, 20 or 30 μM of
paclitaxel. (D) The expression of the indicated proteins in HME or HME/IRIS cells following exposure to 1 μM of paclitaxel for 0, 1 or 3 weeks. (E and F)
The expression of the indicated proteins in the nucleus or cytoplasm of HME or HME/IRIS following exposure to 1 μM of paclitaxel for 0, 1 or 3 weeks.
Activated ERK, JNK and p38 were detected using antibodies specifically detect p-T202/Y204-ERK, p-T183/Y185-JNK, and p-T180/Y182-p38. (G) The effect of
BRCA1-IRIS overexpression on the proliferation of HME cells. (H) The effect of inhibiting ERK (using PD98059), JNK (using SP600125), p38 (using SB203580),
PI3′K/AKT (using LY294002), EGFR (using Erlotinib), ErbB2 (using CP-724714), EGFR/ErbB2 (using Lapatinib), and EGFR/ErbB2/ErbB3 (using Sapitinib) on the
survival of HME or HME/IRIS cells. Values represent the means of experiments that were performed in triplicate done three separate times, *** = P ≤0.001
(compared to control in each cell line). (I) Schematic representation of the data so far. EGFR, ErbB2 and ErbB3, epidermal growth factor receptor 1, 2 and
3, respectively; HME, human mammary epithelial cells; TNBC, triple negative breast cancer.
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on S308/T473 and FOXO3a phosphorylation on T32
(AKT target) in HME cells, while intrinsically high p-AKT
and p-FOXO levels in HME/IRIS cells remained unchanged
after treatment were documented (Figure 1C, right). In
keeping with that, a paclitaxel-acquired decrease in total
FOXO3a and FOXO1 levels in HME cells, while already
low and remained so in HME/IRIS cells following paclitaxel
treatment were observed (Figure 1C, right). In line
with that, a paclitaxel-acquired increase in FOXO targets;
for example, Cyclin D1 and survivin (also known
BRCA1-IRIS targets, see [34-37]) in HME, whereas
intrinsically high levels remained unchanged in HME/
IRIS cells were detected (Figure 1C, right).
To ascertain that even further, we generated paclitaxel-
resistant HME and HME/IRIS cells by exposing them to
10 μM of paclitaxel for 1 or 3 weeks (cells were then
propagated in paclitaxel-free media). Consistent with
the data described above, these paclitaxel-resistant
HME cells also showed a paclitaxel-acquired increase
in BRCA1-IRIS, EGFR, ErbB2, ErbB3, p-AKT, p-FOXO3a,
concurrent with decrease in total FOXO3a and FOXO1
and increase in Cyclin D1, survivin and Bcl-xL in HME
(Figure 1D). All were intrinsic in HME/IRIS cells and
remained unchanged after drug treatment (Figure 1D).
Taken together, these data suggest that intrinsic or
paclitaxel-acquired resistance in TNBC cells is due to high
expression level of BRCA1-IRIS.
BRCA1-IRIS overexpression promotes FOXO3a
degradation
Phosphorylation by AKT and/or ERK promotes FOXO3a
nuclear exclusion and degradation [28]. Total AKT levels
were not changed in the cytoplasm or the nucleus of
paclitaxel-resistant HME or HME/IRIS cells (Figure 1E). In
contrast, the level of p-AKT was slightly higher in the
cytoplasm, while slightly lower in the nucleus of paclitaxel-
resistant HME cells than HME/IRIS cells (Figure 1E).
While similar in the cytoplasm, total ERK decreased in the
nucleus of paclitaxel-resistant HME and HME/IRIS cells
(Figure 1E). The level of p-ERK increased in the cytoplasm
of paclitaxel-resistant HME cells, decreased in the cyto-
plasm of paclitaxel-resistant HME/IRIS cells, while
remained largely unchanged in the nucleus of resistant
HME and HME/IRIS cells (Figure 1E). The level of
p-FOXO increased in the cytoplasm of paclitaxel-
resistant HME cells, while it decreased in the cytoplasm of
resistant HME/IRIS cells (Figure 1E). No p-FOXO in the
nucleus of paclitaxel-resistant HME cells, while relatively
high level in paclitaxel-resistant HME/IRIS cells was
detected (Figure 1E). MDM2 and Skp2 have been
previously implicated in mono- and poly-ubiquitylation,
respectively of FOXO proteins. We detected increased
level of MDM2 and Skp2 in the cytoplasm and nucleus ofthe paclitaxel-resistant HME and HME/IRIS (Figure 1E).
Taken together, these data suggest that intrinsic or
paclitaxel-acquired increase in MDM2 and Skp2 expres-
sion induced by BRCA1-IRIS overexpression coopera-
tively promote FOXO3a ubiquitylation and proteasomal
degradation in HME/IRIS and HME cells, respectively.
Additional signaling pathways induced by BRCA1-IRIS
overexpression
We also observed that compared to HME, HME/IRIS
cells contained lower ERK and p38 while higher JNK
levels in the cytoplasm and nucleus (Figure 1F). In contrast,
compared to HME cells, HME/IRIS cells contained lower
level of p-ERK in the cytoplasm but higher level in the
nucleus (Figure 1F), higher levels of p-JNK in the cytoplasm
and nucleus (Figure 1F), and similar level of p-p38 in the
cytoplasm but no p-p38 in the nucleus in both cell lines
(Figure 1F). Taken together, these data suggest additional
signaling pathways induced by BRCA1-IRIS overexpression
[34-36] that could also be involved in promoting FOXO3a
degradation.
Selective sensitivity of BRCA1-IRIS-overexpressing cells to
drugs against these pathways
The above data imply BRCA1-IRIS-overexpressing cells
sensitivity to inactivation of these pathways. To evaluate
that, similar numbers of HME or HME/IRIS cells were
grown in the presence of 10 μM of ERK (PD98059), JNK
(SP600125), p38 (SB203580), PI3′K/AKT (LY294002), EGFR
(Erlotinib), ErbB2 (CP-724714), EGFR/ ErbB2 (Lapatinib) or
EGFR/ErbB2/ErbB3 (Sapitnib) inhibitors for 24 h.
First, because BRCA1-IRIS overexpression significantly
increased proliferation of HME cells (Figure 1G and see
[34-36]) the data obtained with the inhibitors were
normalized to untreated cells of each cell line, separately.
None of the drugs at the concentration used had an
effect on HME cells survival (white bars in Figure 1H).
In contrast, ERK, JNK, PI3′K/AKT, EGFR and ErbB2
inhibitors decreased HME/IRIS cells survival by approxi-
mately 50% compared to untreated HME/IRIS cells
(black bars in Figure 1H). More dramatic effect was
noticed using the dual EGFR/ErbB2 inhibitor and even
more dramatic using the inhibitor that targets EGFR,
ErbB2 and ErbB3 at the same time (Figure 1H). Taken
together, these data suggest that BRCA1-IRIS-overexpressing
cells are more sensitive to drugs that block EGFR-ErbB2
and ErbB2-ErbB3 complexes and their downstream
signaling pathways. Schematic representation of all the
above data is presented in Figure 1I.
A BRCA1-IRIS mimetic inhibitory peptide abolishes
BRCA1-IRIS expression and functions
The above data seem to argue that inactivating BRCA1-
IRIS could sensitize TNBC cells to paclitaxel. Since
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following reasons motivated us to pursue the inhibitory
mimetic peptide approach instead. First, previous results
suggested that BRCA1-IRIS connect with partners using
a domain in its C-terminus [32,34]. Second, unlike
full-length BRCA1-IRIS, overexpression of an intronless
BRCA1-IRIS (Δint11, missing the 34 amino acid domain
encoded by intron 11) failed to induce expression of
targets such as; Cyclin D1, survivin and vimentin in HME
cells (see Figure 2A and [34-38,44]). Based on these facts,
we hypothesized that BRCA1-IRIS forms an oncogenic
complex(es) by connecting with other factor(s) (Figure 2B)Figure 2 BRCA1-IRIS inhibitory peptide effect on TNBC cells survival,
with empty vector, Myc-tagged wild-type BRCA1-IRIS (wt IRIS) or Myc-tagg
48 h. (B) Schematic representation of the proposed function of BRCA1-IRIS
black sequence is penetrating signal and red sequence is BRCA1-IRIS intron
concentrations of IRIS peptide. Values are means of triplicates done three s
BRCA1-IRIS expression in the indicated cell lines. (E) Effect of increasing con
luciferase or BRCA1-IRIS silencing. Values are means of triplicates done thre
(5 μM) in the indicated TNBC cell lines and 0, 5, 10 and 20 μM of paclitaxel
effect of 0.5 μM (HME) or 5 μM (other cell lines) of IRIS peptide on BRCA1-I
increasing concentrations of IRIS peptide alone (light-colored lines) or the c
Values are means of triplicates done three separate times. (G, lower) The g
following exposure to increasing concentrations of IRIS peptide. Values are
of the indicated proteins in MDA-MB-231 and MDA-MB-468 cells following
peptide, 10 μM of PI3′K/AKT inhibitor (LY294002) or ERK1/2 inhibitor (PD98
human mammary epithelial cells; TNBC, triple negative breast cancer.and that transduction of BRCA1-IRIS intron 11 domain
could in a dominant-negative fashion disrupt this
interaction leading to loss of BRCA1-IRIS oncogenic
effect (Figure 2B).
To test this hypothesis, we synthesized a peptide
(hereafter IRIS peptide) consisting of the BRCA1-IRIS
intron 11 peptide (red sequence in Figure 2C) fused
to a cell/nuclear penetrating signal at the N-terminus
(black sequence in Figure 2C). Equal numbers of HME,
HME/IRIS, MDA-MB-231, MDA-MB-468 and BT549
cells were exposed to increasing concentrations of scram-
bled or IRIS peptides for 48 h. Compared to scrambledin vitro. (A) Expression of indicated proteins in HME cells transfected
ed mutant BRCA1-IRIS (missing the intron 11 domain, Δint 11 IRIS) for
intron 11 domain and peptide. (C) BRCA1-IRIS inhibitory peptide;
11 domain. (D) Survival of the indicated cells exposed to increasing
eparate times. Inset: effect of 5 μM of scrambled or IRIS peptide on
centrations of IRIS peptide on the indicated cell lines following
e separate times. (F) The synergistic effect between IRIS peptide
. Values are means of triplicates done three separate times. Inset:
RIS expression. (G, upper) Effect of paclitaxel at 1 μM alone (white bar),
ombination (dark-colored lines) on the survival of indicated cells.
radual increase in activated caspase 3/7 in the indicated cells
means of triplicates done three separate times. (H) The expression
transfection of BRCA1-IRIS siRNA, or the exposure to 5 μM IRIS
059). (I) Schematic representation of the data in Figure 2. HME,
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all cell lines. HME cells showed an IC50 of approximately
0.5 μM, whereas HME/IRIS and the TNBC cell lines an
IC50 of 5 to 7.5 μM (Figure 2D). On the molecular level,
treatment with 5 μM of IRIS peptide for 24 h almost com-
pletely abolished BRCA1-IRIS expression in all these cell
lines compared to treatment with 5 μM scrambled peptide
(inset in Figure 2D). Taken together, these data support
our hypothesis that IRIS peptide acts as a dominant nega-
tive in TNBC cells suppressing BRCA1-IRIS oncognecity
by destabilization of the protein (Figure 2B).
To ascertain the specificity of IRIS peptide even
further, HME, HME/IRIS, MDA-MB-231, MDA-MB-468
and BT549 cells were first transfected with siLuc or
siIRIS for 48 h before exposing them to increasing
concentrations of IRIS peptide for another 48 h. Gradual
decrease in all cell lines was detected in siLuc-transfected
cells following treatment with increasing concentrations
of IRIS peptide (Figure 2E, left). In contrast, BRCA1-IRIS
silencing significantly decreased survival of all cell lines
(Figure 2E, right) and treatment with IRIS peptide had no
additive effect on these cells even at higher concentrations
(Figure 2E, right). These data, suggest that IRIS peptide
targets BRCA1-IRIS specifically leading to significant
growth retardation and cell death in TNBC cells, in vitro.
BRCA1-IRIS inhibition sensitizes breast cancer cells to low
paclitaxel concentrations, in vitro
Whether inactivating BRCA1-IRIS could sensitize TNBC
cells to paclitaxel was investigated next. HME cells
exposed to 0.5 μM or HME/IRIS, MDA-MB-231,
MDA-MB-468 and BT549 cells exposed to 5 μM of
IRIS peptide were exposed or not to 5, 10 or 20 μM
of paclitaxel for an additional 24 h. At these concentrations,
IRIS peptide completely abolished BRCA1-IRIS expression
from all cell lines (Figure 2F, inset) and reduced survival by
approximately 50% in all cell lines (Figure 2F). While
paclitaxel also decreased survival of all cell lines that
gradually increased with increasing the concentration,
the combination had even more pronounced effect on
the survival of all cell lines (Figure 2F).
To identify the lowest paclitaxel concentration that
could synergize with IRIS peptide, MDA-MB-231 and
MDA-MB468 cells were treated with 1 μM of paclitaxel,
increasing concentrations of IRIS peptide or both for
24 h. As shown above, survival gradually decreased
with increasing IRIS peptide concentration in both
cell lines (light-colored lines in Figure 2G, upper),
which correlated very well with gradual increase in
activated caspase 3 and 7 in both cell lines (Figure 2G,
lower). Although at this very low concentration of
paclitaxel we detected no cell death in either cell line
(white bar in Figure 2G, upper), addition of 1 μM
additively increased the effect of IRIS peptide on thesurvival of both cell lines (dark-colored lines in Figure 2G,
upper). Taken together, these data suggest synergy between
BRCA1-IRIS inhibition and very low concentrations of
paclitaxel on the survival of TNBC cells, in vitro.
Molecular comparison between the effect of BRCA1-IRIS
silencing or inactivation in TNBC cells
To further explore IRIS peptide mechanism of action on cell
survival and at the same time generate further evidence for
its specificity, MDA-MB-231 and MDA-MB-468 cells were
silenced from BRCA1-IRIS for 72 h, treated with 5 μM of
IRIS peptide for 24 h and for comparison cells were exposed
to 10 μM of the PI3′K/AKT inhibitor; LY294002 (hereafter
LY) or the ERK inhibitor; PD98059 (hereafter PD) for 24 h.
Surprisingly, LY and PD beside inactivating AKT and ERK,
respectively with no effect on the total proteins, both also
significantly decreased BRCA1-IRIS expression (Figure 2H).
In contrast, BRCA1-IRIS silencing or inactivation not only
decreased BRCA1-IRIS expression level, but also total AKT
and p-AKT levels in both cell lines (Figure 2H).
Concurrently, LY, IRIS peptide and BRCA1-IRIS silencing
all significantly decreased p-FOXO3a level and increased
total FOXO3a level in both cell lines, which again was
correlated with significant decrease in MDM2 and/or Skp2
expression (Figure 2H). Surprisingly, LY and IRIS peptide
(and to a lesser degree BRCA1-IRIS silencing) had little
effect on total ERK expression in this experiment but
increased the level of p-ERK in both cell lines (Figure 2H).
Taken together, these data, in addition to confirming
the specificity of the peptide, they define a molecular
mechanism of action for IRIS peptide in TNBC cell sur-
vival, a positive-feedback loop between BRCA1-IRIS and
AKT signaling in both cell lines (see model in Figure 2I).
BRCA1-IRIS overexpression induces in HME cells, while
silencing or inactivation inhibits aggressiveness in TNBC
cells, in vitro
Next, we asked whether BRCA1-IRIS depletion or
inactivation impacts TNBC cells aggressiveness. To evaluate
that, we used one of the best assays, ‘growth in three-
dimensional culture’. HME, HME/IRIS, MDA-MB-231 or
MDA-MB-468 cells stably expressing shcontrol or shIRIS
were layered on matrigel-coated wells. Additionally,
parental cell lines layered on matrigel-coated wells
were grown in the presence of scrambled or IRIS
peptide (added every third day). Ten days later, HME
cells formed acini that were small/round/organized,
composed of 40 to 50 cells and hollow in the middle
(see Figure 3A and N1). In contrast, at day 10, acini formed
by HME/IRIS (Figure 3D), MDA-MB-231 (Figure 3G)
or MDA-MB-468 (Figure 3J) were much larger, non-
round and unorganized with large protrusions, and
were filled with cells on the inside resembling DCIS
(Figure 3N2 and N3).
Figure 3 BRCA1-IRIS overexpression promotes aggressiveness in HME cells, while inactivation inhibits it in TNBC cells. Representative images
showing acini formation in low growth factor matrigel-coated wells in the presence of vehicle, shIRIS or IRIS peptide in HME (A-C) HME/IRIS
(D-F) MDA-MB-231 (G-I) and MDA-MB-468 (J-L) cell lines at day 10. IRIS peptide was added at 0.5 μM (HME) or 5 μM (the other cell lines). Scale bar
in A-L = 400 μm. (M) Quantitative analysis of the number and phenotype of acini formed using HME and HME/IRIS (upper) or MDA-MB-231 and
MDA-MB-468 (lower) following the above mentioned treatments at day 10. (N1-N4) Acini formed by HME, HME/IRIS, MDA-MB-468 and
MDA-MB-468/shIRIS, respectively. The expression of the indicated proteins in acini formed using HME (O1, P1, R1 and S1), HME/IRIS
(O2, P2, R2 and S2), MDA-MB-468 (O3, P3, R3 and S3) and MDA-MB-468/shIRIS (O4, P4, R4 and S4) cells. Scale bar in O1-S4 = 100 μm. HME,
human mammary epithelial cells; TNBC, triple negative breast cancer.
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vation (Figure 3C) completely abolished formation of acini
by HME cells and converted HME/IRIS (Figure 3E and F,
respectively), MDA-MB-231 (Figure 3H and I, respectively)
and MDA-MB468 (Figure 3K and L, respectively) acini
into smaller/rounder/organized acini. These acini also
lacked protrusions and most importantly were hollow on
the inside (see for example Figure 3N4 for MDA-MB-468silenced cells). Quantitatively, BRCA1-IRIS overexpression
led to more than threefold increase in HME cells aggres-
siveness (defined as generation of non-round, non-
organized, large filled with cells acini, Figure 3M, upper),
whereas depletion or inactivation reduced that pheno-
type in TNBC cells by more than threefold (defined
as generation of round, organized, small and hallow
acini Figure 3M, lower).
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silencing inhibits aggressive biomarkers expression in
TNBC cells, in vitro
To correlate these data with expression of aggressiveness
biomarkers, similar acini were processed for immuno-
fluorescence (IF) labeling with EGFR, ErbB2, ErbB3 and
cortactin antibodies. HME acini showed low expression
levels of all biomarkers that when found were, as
expected, restricted to the apical side of the acini (see
Figure 3O1, P1, R1 and S1). In contrast, HME/IRIS acini
showed increase expression of all biomarkers, which
were expressed at the apical as well as the basolateral side
of the acini (Figure 3O2, P2, R2 and S2). MDA-MB-468
acini showed high levels and unrestricted expression of all
aggressiveness biomarkers (Figure 3O3, P3, R3 and S3),
whereas BRCA1-IRIS silencing in MDA-MB-468 cells not
only decreased the expression of all aggressiveness
biomarkers, but also restricted it to the apical side
(Figure 3O4, P4, R4 and S4). Taken together, these
data suggest that BRCA1-IRIS overexpression triggers
a polarization, epithelial to mesenchymal transition
(EMT) and aggressiveness in HME cells, which could
explain the invasive, aggressiveness and unrestricted
growth of HME/IRIS cells in three-dimensional matrigel
and SCID mice [38], and that BRCA1-IRIS silencing in
TNBC cells reverse these phenotypes.
BRCA1-IRIS silencing or inactivation inhibits
tumor-initiating phenotype in TNBC cells, in vitro
It has been suggested recently that a population with
tumor-initiating (that is breast cancer stem-like) capabil-
ities exists within TNBC tumors. To evaluate whether
BRCA1-IRIS inactivation suppress stemness phenotype in
TNBC cells, MDA-MB-231 and MDA-MB-468 cells
stably expressing shcontrol or shIRIS were plated in
ultra-low binding dishes. Additionally parental cells
were also plated in ultra-low binding dishes and
treated with scrambled or IRIS peptide readded to
cells every third day. Mammospheres - a hallmark of
breast cancer stem-like cells - formed within 10 days
were then counted and photographed. Control shRNA
expressing or scrambled peptide-treated MDA-MB-231 or
MDA-MB-468 cells formed many large-size mammo-
spheres (Figure 4A, for MDA-MB-468, identical result was
documented for MDA-MB-231). BRCA1-IRIS silenced
(Figure 4B, for MDA-MB-468, identical data was docu-
mented for MDA-MB-231) or inactivated (Figure 4C, for
MDA-MB-468, identical data was documented for
MDA-MB-231) showed much smaller mammospheres.
Quantitatively, BRCA1-IRIS silencing or inactivation re-
duced the ability of both cell lines to form mammospheres
by approximately threefold (Figure 4D) and whenever
formed their size was approximately threefold smaller
than control cells (Figure 4E).BRCA1-IRIS induces in HME cells, whereas silencing
inhibits stemness biomarkers expression in TNBC cells,
in vitro
To investigate whether altering BRCA1-IRIS alters
stemness biomarkers expression, HME cells were induced
to overexpress BRCA1-IRIS or TNBC cells were silenced
from BRCA1-IRIS, and expression of stemness biomarkers,
Oct-4, Sox-2 and Nanog was analyzed. BRCA1-IRIS
overexpression significantly increased expression of
these biomarkers in HME cells (Figure 4F). Conversely,
BRCA1-IRIS silencing significantly decreased the
expression of these biomarkers in MDA-MB-231 and
MDA-MB-468 cells (Figure 4G). Taken together, these
data suggest that inactivating BRCA1-IRIS suppresses the
tumor-initiating phenotype, implicated in aggressiveness
and recurrence of TNBC cells.
BRCA1-IRIS silencing or inactivation inhibits migration
and invasion in TNBC cells, in vitro
TNBC tumor cells often possess enhanced migration and
invasion capabilities. To assess whether BRCA1-IRIS plays
a role in these phenotypes as well, we plated MDA-MB-468
cells stably expressing shcontrol or shIRIS inside inserts
placed in the middle of wells of 6-well plates. When conflu-
ent, inserts were removed, dying and dislodged cells were
washed away and cells were allowed to migrate for 24 h.
MDA-MB-468 cells expressing shcontrol showed robust
migration capabilities as evident by filling the empty space
left after the removal of the insert (see white arrow in
Figure 4H) as well as the outward migration (see arrowheads
in Figure 4H). BRCA1-IRIS-silenced MDA-MB-468 cells,
on the other hand, almost completely lost their migratory
ability (see white arrows and arrowheads in Figure 4I).
To study whether BRCA1-IRIS silencing or inactivation
affects TNBC cells invasion ability, MDA-MB-231 and
MDA-MB-468 cells expressing shcontrol or shIRIS were
layered on matrigel-coated Boyden chambers transwells.
Additionally, parental cells were layered on transwells and
grown in the presence of scrambled or IRIS peptide. To
migrate to the lower side of the chamber or the bottom
well, cells must first digest the matrigel. Four days later, a
significant number of control cells (expressing empty
vector or treated with scrambled peptide) invaded the
matrigel and migrated to the lower side of the chambers
(Figure 5A for MDA-MB-231, 5D for MDA-MB-468) and
the bottom well (Figure 5H for MDA-MB-231, 5K for
MDA-MB-468) in both cell lines. BRCA1-IRIS-silenced
(Figure 5B and I, for MDA-MB-231, 5E and L for
MDA-MB-468) or -inactivated (Figure 5C and J for
MDA-MB-231, 5F and M for MDA-MB-468) cells almost
completely lost their ability to invade and migrate. Quanti-
tatively, BRCA1-IRIS silencing or inactivation reduced the
invasive/migratory ability of these TNBC cells by approxi-
mately 100-fold (see Figure 5G for cells on the reverse
Figure 4 BRCA1-IRIS overexpression promotes tumor-initiating phenotype in HME cells, while inactivation suppresses it in TNBC cells.
(A-C) Representative images showing mammosphere formation in MDA-MB-468 cells following control treatments (A), BRCA1-IRIS silencing (B) or
inactivation using IRIS peptide (C) at day 10. Scale bar in A-C = 1,000 μm. Quantitative analysis of the number (E) or diameter (F) of mammospheres
developed using MDA-MB-231 or MDA-Mb-468 cells after vehicles, BRCA1-IRIS silencing or BRCA1-IRIS inactivation using IRIS peptide. (G) The
expression of the indicted stemness biomarkers in HME or BRCA1-IRIS overexpressing HME cells or MDA-MB-231 and MDA-MB468 expressing or
silenced from BRCA1-IRIS. Representative images of the migration of MDA-MB-468 (H) or MDA-MB-468 expressing IRIS shRNA (I). In both images
arrows show intervening spaces left by the insert that were filled by MDA-MB-468 (24 h later) and not in BRCA1-IRIS-silenced MD-MB-468 and in both
images arrowheads show the distance MDA-MB-468 cells travelled outward and the lack of such migration in BRCA1-IRIS-silenced MDA-MB-468 cells.
HME, human mammary epithelial cells; TNBC, triple negative breast cancer.
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bottom well).
BRCA1-IRIS overexpression induces in HME cells, whereas
silencing inhibits EMT and invasion biomarkers
expression in TNBC cells, in vitro
To investigate whether altering BRCA1-IRIS alters EMT
and invasion biomarkers expression, HME cells were
induced to overexpress BRCA1-IRIS or TNBC cells were
silenced from BRCA1-IRIS. BRCA1-IRIS overexpression
in HME cells significantly enhanced expression of EMT
biomarkers, such as slug, snail, and twist (Figure 5O),
as well as invasion biomarkers, such as N-cadherin
(compare Figure 5P2 to P1), FOXC2 (compare Figure 5Q2
to Q1) and vimentin (compare Figure 5R2 to R1)
and suppressed expression of E-cadherin (compare
Figure 5S2 to S1). Conversely, BRCA1-IRIS silencing
in MDA-MB-231 or MDA-MB-468 cells significantly
reduced expression of slug, snail and twist (Figure 5O), as
well as N-cadherin (compare Figure 5P4 to P3), FOXC2
(compare Figure 5Q4 to Q3) and vimentin (compareFigure 5R4 to R3) and enhanced E-cadherin expression
(compare Figure 5S4 to S3). Taken together, these data
suggest that BRCA1-IRIS overexpression triggers EMT,
migration and invasion in TNBC cells.
Elevated BRCA1-IRIS and survivin, while lack of FOXO3a
expression in aggressive human breast tumors
Previously, we showed elevated BRCA1-IRIS expression
in approximately 80% of breast tumors (>800 tumor
samples were analyzed) that was correlated with elevated
p-AKT and survivin expression (Ref. [38]). To correlate
these data to FOXO3a expression, tissue microarrays
consisted of normal/cancer adjacent (n = 66), DCIS
(n = 167), invasive (n = 179) and metastatic (n = 99)
samples were immunohistochemically stained with
anti-BRCA1-IRIS, -survivin and -FOXO3a antibodies.
Semi-quantitative scoring analysis (see Methods) showed
that BRCA1-IRIS (P <0.0001, Figure 6A) and survivin
(P <0.0001, Figure 6B) expression significantly increased
concurrently with the increase in tumor aggressive-
ness. Indeed, aside from the fact that more cells per
Figure 5 BRCA1-IRIS overexpression promotes EMT and invasion in HME cells, while inactivation suppresses them in TNBC cells. (A)
Representative images showing the invasion ability of MDA-MB-231 (A and H) and MDA-MB-468 (D and K) cells through matrigel-coated Boyden
chambers and the significant retardation of this invasion ability following BRCA1-IRIS silencing in MDA-MB-231 (B and I) and MDA-MB-468 (E and L) or
BRCA1-IRIS inactivation using IRIS peptide in MDA-MB-231 (C and J) and MDA-MB-468 (F and M) cells on day 7. Scale bars in A-F and H-M= 1,000 μm.
Quantitative analysis of invasive ability of the indicated cells shown as cells travelled to the other side of the transwells (G) or jumped to the lower well
of the Boyden chamber (N). (O) The expression of the indicated EMT biomarkers in HME or BRCA1-IRIS overexpressing HME cells as well as MDA-MB-231
or MDA-MB-468 cells expressing or silenced from BRCA1-IRIS. Please note that BRCA1-IRIS and H2B blots used are the same as those used in Figure 4G.
The expression of the indicated EMT/invasion biomarkers in HME (P1, Q1, R1, and S1), BRCA1-IRIS-overexpressing HME (P2, Q2, R2 and S2),
MDA-MB-468 (P3, Q3, R3 and S3) or MDA-MB-468 silenced from BRCA1-IRIS (P4, Q4, R4 and S4) cells. Scale bars in P1-P4 and S1-S4 = 20 μm,
and in Q1-Q4 and R1-R4 = 50 μm. EMT, epithelial to mesenchymal transition; HME, human mammary epithelial cells; TNBC, triple negative breast cancer.
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the intensity of the staining per cell also increased as
disease progressed (data not shown).
Since p-AKT phosphorylation restricts FOXO3a nuclear
translocation and promotes its degradation, we evaluatedthe presence as well as the cellular localization of
FOXO3a in these tumors. We evaluate the nuclear (N),
cytoplasmic (C), both (NC) or negative (0) expression of
FOXO3a. We found that FOXO3a staining was N in
the majority of BRCA1-IRIS expressing (IRIS+) and
Figure 6 Elevated BRCA1-IRIS and survivin and lack of FOXO3a expression correlates with breast tumors aggressiveness. Paraffin-embedded
tissue microarray sections were examined by immunohistochemistry with anti-BRCA1-IRIS, survivin and FOXO3a mAb. (A and B) BRCA1-IRIS
and survivin, respectively staining scores in normal (n = 66), DCIS (n = 167), invasive (n = 179) and metastatic (n = 99) breast cancer tissue
samples. (C and D) BRCA1-IRIS and survivin, respectively staining scores per field as compared to the localization of FOXO3a in each cell
in normal (n = 66), DCIS (n = 167), invasive (n = 179) and metastatic (n = 99) breast cancer tissue samples. (E) Percentage of probability of
disease-free survival in patients with TNBC tumors overexpressing low (blue line) vs. middle/high (red line) levels of EGFR/AKT/MDM2/Skp2/survivin as
a surrogate for BRCA-IRIS overexpression. DCIS, ductal carcinoma in situ; FOXO3a, Forkhead box class OAKT3a; mAb, monoclonal antibody; TNBC, triple
negative breast cancer.
Blanchard et al. Breast Cancer Research  (2015) 17:5 Page 13 of 18survivin-expressing (survivin+) normal tissues (all P <0.0001,
Figure 6C and D). In contrast, the majority of IRIS+
or survivin+ DCIS tumors showed 0, with few tumors
showing N staining (P <0.0001, Figure 6C and D).
The majority of IRIS+ invasive tumors showed 0, with few
tumors showing C FOXO3a staining, whereas the majority
of the survivin+ invasive tumors were 0, with few tumorsshowing N FOXO3a staining (P <0.0001, Figure 6C and D).
Finally, nearly all IRIS+ or survivin+ metastatic breast
cancer tissues were 0 for FOXO3a (P <0.0001, Figure 6C
and D). Taken together, these data suggest that during
breast cancer progression, elevated BRCA1-IRIS expression
activates AKT that decreases FOXO3a expression leading
to elevated survivin expression.
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BRCA1-IRIS signature-expressing TNBC tumors
Based on the data presented above we concluded that
BRCA1-IRIS-overexpressing TNBC cells show concurrent
elevation in the expression of ‘EGFR, AKT, MDM2,
Skp2 and survivin’. Considering this short list as a
BRCA1-IRIS-overexpression signature in TNBC tumors,
we conducted an association assessment of this signature
and disease-free survival (DFS) using a combined breast
cancer cohort from seven Gene Expression Omnibus
(GEO) studies (GSE2034, GSE2603, GSE3494, GSE4922,
GSE6532, GSE7390 and GSE12093). Patients with positive
status for estrogen, progesterone and HER2 were
excluded leading to a size of 576 cases. The standardized
BRCA1-IRIS signature expression levels were pooled
together and considered as explanatory variables in a Cox
model on DFS. Based on the estimation result of the Cox
model, we developed a prognostic index combining the
expression levels of BRCA1-IRIS overexpression signature:
‘Prognostic index = EGFR + 2 x AKT + 2 x MDM2 + 2 x
Skp2 + 2 x survivin’, which was evaluated for the entire
sample. The patient cohort was further categorized into
low- versus middle/high-expressing groups by using the
lower tertile as the cutoff value. Using Kaplan-Meier
method and group-wise comparison in DFS done using
the log-rank test, this analysis showed that among the co-
hort tested, patients with middle/high expression levels of
BRCA1-IRIS overexpression signature showed signifi-
cantly (Log-rank P = 0.016) shorter DFS compared to
those showing low expression levels (Figure 6E). Taken to-
gether, these data suggest that elevated BRCA1-IRIS level
is a poor overall prognosis in patients with TNBC disease.
BRCA1-IRIS silencing or inactivation blocks TNBC tumor
formation, maintenance and sensitizes them to low
paclitaxel concentrations, in vivo
We showed previously that BRCA1-IRIS-overexpressing
HME cells form aggressive TNBC tumors lacking
BRCA1 expression [38]. To evaluate whether BRCA1-IRIS
overexpression is indeed required for TNBC tumor forma-
tion and/or maintenance, MDA-MB-231 or MDA-MB-468
(2 x 106) cells expressing shcontrol or shIRIS were injected
in mammary fat pads (second left and fourth right) of 6- to
8-week-old female SCID mice (mice, n = 6/cell line→
tumors, n = 12/cell line). Control shRNA-expressing
cells formed tumors that reached approximately 750 mm3
within 4 weeks (black line for MDA-MB-231 and blue line
for MDA-MB-468 in Figure 7A). BRCA1-IRIS-silenced
MDA-MB-231 formed very small tumors that were
approximately 100 mm3 by 4 weeks (red line in Figure 7A),
and BRCA1-IRIS-silenced MDA-MB-468 cells failed com-
pletely to form any tumors (green line in Figure 7A). These
data, suggest that BRCA1-IRIS overexpression is required
for TNBC tumor formation.Moreover, MDA-MB-468 or MDA-MB-231 (2 x 106)
cells were injected in mammary fat pads (second left and
fourth right) of 6- to 8-week-old Nu/Nu female mice
(mice, n = 24→ tumors, n = 48). When tumors reached
approximately 0.1 cm3 in volume, the mice were divided
into four groups that were treated with vehicles (that is
DMSO injected intraperitoneally (i.p.) + scrambled peptide
injected directly into tumors (i.t.), mice, n = 6→ tumors,
n = 12), paclitaxel (10 mg/kg, i.p., mice, n = 6→ tumors,
n = 12), IRIS peptide at (10 mg/kg, i.t., mice, n = 6→
tumors, n = 12), or paclitaxel + IRIS peptide (at half the
concentrations, same routes, mice, n = 6→ tumors, n = 12).
Drugs were delivered every third day for total of four injec-
tions (see red arrows in Figure 7B). Tumors were measured
using caliper three times per week and collected at
the end of the experiment (day 12). At day 12, tumors in
vehicle-treated mice became approximately 3.5 times their
original size at day 0 (see black line in Figure 7B and 7C).
Impressively, at day 12, tumors in IRIS peptide-treated
mice, actually shrunk to approximately 25% their original
size at day 0 (see red line in Figure 7B and 7C). Taken to-
gether, these data suggest that BRCA1-IRIS overexpression
is important for TNBC tumor maintenance.
Moreover, at day 12, paclitaxel treatment showed some
effect, but tumors still grew to approximately 1.5 times
their original size at day 0 (see blue line in Figure 7B and
7C). More importantly, tumors treated with the combin-
ation ‘IRIS peptide + paclitaxel’ (at only half the above
concentrations) shrunk to <15% of their original size at day
0 (see green line in Figure 7B and 7C). Taken together,
these data suggest that inactivating BRCA1-IRIS sensitizes
TNBC tumors to low paclitaxel concentrations, in vivo.
BRCA1-IRIS inactivation suppresses paclitaxel-induced
overexpression in BRCA1-IRIS→ survivin, in vivo
Finally, to correlate the above in vivo efficacy data of IRIS
peptide to expression of BRCA1-IRIS and hence survivin in
these tumors, we stained adjacent sections from the tumors
developed above with hematoxylin and eosin (H&E) or with
IHC for BRCA1-IRIS or survivin. As expected, in controls-
treated tumors, BRCA1-IRIS and survivin expression was
high (Figure 7D, upper row), and as described above, the
expression increased even further by paclitaxel treatment
(even though tumors were smaller, Figure 7D, third row).
In contrast, the expression of both proteins was completely
abolished in tumors treated with IRIS peptide (Figure 7D,
second row) or the combination (even at only half the
concentrations, Figure 7D, fourth row). Taken together,
these data could explain the acquired paclitaxel resistant
recurrences observed in TNBC patients.
Discussion
Development of chemotherapy-resistant recurrences plays
a major role in breast cancer mortalities [43]. Paclitaxel
Figure 7 BRCA1-IRIS overexpression promotes TNBC formation and maintenance, while inactivation sensitizes them to low paclitaxel
concentrations. (A) Volumes of tumors developed in SCID mice using MDA-MB-231/shcontrol (black line, n = 6), MDA-MB-231/shIRIS (red line,
n = 6), MDA-MB-468/shcontrol (blue line, n = 6) or MDA-MB-468/shIRIS (green line, n = 6). (B) The effect of vehicle (black line, n = 6), paclitaxel (10
mg/kg, delivered i.p., blue line, n = 6), IRIS peptide (10 mg/kg, delivered i.t., red line, n = 6), or both (at half the concentrations, delivered through
the same routes, green line, n = 6) on an established MDA-MB-468 tumors. Red arrows show the times of the drug administration. ** = P ≤0.001
and *** = P ≤0.0001. (C) Shows representative images of treated mice as described in (B) at day 12 (upper) or representative images of tumors
isolated from these mice following the treatments also at day 12 (lower). (D) Representative images of the sections from tumors shown in (B and C)
stained with H&E (left), BRCA1-IRIS (middle), survivin (right) antibodies. Scale bar is D = 100 μm. H&E, hematoxylin and eosin; i.p., intraperitoneally; i.t.,
intratumorally; TNBC, triple negative breast cancer.
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manent mitotic arrest. However, adaptation that develops
in some paclitaxel-treated tumor cells can lead to tumor
progression [45,46]. BRCA1-IRIS expression is elevated
in the majority of breast cancers, including TNBCs [38].
BRCA1-IRIS-overexpressing tumors show adverse outcomes,
progression and metastasis [38].
Here, we present extensive evidence showing a paclitaxel-
resistance-promoting role for BRCA1-IRIS overexpression
in TNBC tumor cells, in vitro and in vivo. BRCA1-IRIS
overexpression drastically diminishes paclitaxel efficacy asevidenced by decreased apoptosis of treated cells
in vitro (Figure 2) and in vivo (Figure 7). Only following
BRCA1-IRIS silencing or inactivation (using a novel
BRCA1-IRIS inhibitory peptide) was the efficacy of
paclitaxel restored. BRCA1-IRIS mediates this resist-
ance by upregulating expression of survivin through
activation of AKT and/or inactivation of FOXO3a
in vitro and in vivo. In addition, increased expression
of other prominent apoptosis-suppressing proteins,
such as Bcl-2, Bcl-xL and NF-κB by BRCA1-IRIS could
also play a role.
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described above is the fact that at low concentration,
paclitaxel upregulates BRCA1-IRIS expression in normal
(see above) as well as low BRCA1-IRIS-expressing breast
cancer cells (not shown). This observation may suggest
that paclitaxel promotes its own resistance in patients by
selecting certain tumor cells to survive and repopulate
the tumor by upregulating BRCA1-IRIS in them. More
seriously still is the prospective that the generation of
new tumor not just recurrent tumor developed after
treatment from normal cells. The mechanism responsible
for paclitaxel (low concentration)-induced BRCA1-IRIS
expression is being investigated. However, overall, these
findings indicate that BRCA1-IRIS upregulation is involved
in TNBCs intrinsic and acquired paclitaxel resistance and
its inhibition can be pursued as a therapeutic option
to reverse this resistance in TNBC patients.
The specificity of BRCA1-IRIS-overexpression-induced
acquired paclitaxel resistance is shown here by genetic
manipulation of BRCA1-IRIS in three aggressive TNBC
lines. In addition, we achieved sensitization to lower con-
centrations of paclitaxel-induced apoptosis, in vitro and
in vivo and corresponding reduction in the aforemen-
tioned pathways when BRCA1-IRIS activity was reduced
in these cell lines using the novel IRIS peptide. This was
further supported by the fact that one of the most promin-
ent effects of low paclitaxel concentration-induced resist-
ance in HME cells was BRCA1-IRIS overexpression,
which was followed by upregulation of the survival path-
ways described above. Taken together, these data strongly
support the notion that whether intrinsically or acquired
following paclitaxel (especially low concentration) treat-
ment, the upregulation in BRCA1-IRIS in TNBC cells is a
major obstacle against obtaining major efficacy for pacli-
taxel, especially in patients with metastatic breast cancer.
We therefore propose that inhibiting BRCA1-IRIS expres-
sion and/or activity could sensitize these tumors to pacli-
taxel and perhaps as our data suggest, lower and less toxic
concentrations of this chemotherapy.
Our data, especially with the IRIS peptide, seem to
suggest that intact AKT is more important for TNBC
than intact ERK pathway since prior to promoting cell
death in TNBC cells, BRCA1-IRIS silencing or inactivation
inactivated the AKT pathway but had no or the opposite
effect on ERK pathway. However, we cannot rule out
the possibility that to completely eradicate BRCA1-IRIS-
overexpressing TNBC cells, ERK1/2 inhibitors must be
combined with AKT and/or BRCA1-IRIS inhibitors. It is
also possible - since we cannot distinguish between ERK1
or ERK2 activation in these assays - that the two act
in a different manner. Interestingly, AKT - and to a
lesser extent ERK - inactivation significantly decreased
BRCA1-IRIS level in the TNBCs cell lines tested. This
implies a feed-forward mechanism is at work inTNBCs (possibly other cell types as well). It is possible that
p-AKT enhances BRCA1-IRIS expression, which enhances
AKT expression and activation. One of two possibilities
might account for this phenomenon. The first is that
through silencing BRCA1 (see [38,44]), BRCA1-IRIS is able
to prevent AKT ubiquitination and degradation as was
previously shown. Alternatively, the two events could be
unconnected and merely a consequence of other activities
in TNBC cells. Whatever the explanation is, a positive
feedback mechanism between BRCA1-IRIS and AKT
pathways is directly correlated with the BRCA1-IRIS
chemotherapy resistance-inducing role in TNBC survival.
Mechanistically, BRCA1-IRIS-dependent paclitaxel
resistance could be mediated by pro-survival autocrine
signaling loops, such as those shown here, namely
EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3. Although
paclitaxel-mediated increases in the expression of some
oncogenes have been previously reported in both human
patients with breast cancer [46] and experimental breast
cancer models [47], this is the first study that analyzed
co-expression of BRCA1-IRIS and ErbB family members.
This evidence strongly suggests that therapy-induced
activation of BRCA1-IRIS pathway promotes tumor cell
survival through autocrine signaling loops. However,
secondary pathways initiated from tumor stromal cells are
also possible [48]. Indeed, the fact that intrinsic or
paclitaxel-acquired upregulation of BRCA1-IRIS induced
expression and activation of NF-κB, as evidenced by
increased expression and nuclear accumulation of p65
[44], could lead to, among other effects, transcription and
secretion of a plethora of inflammatory cytokines, such as
interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis
factor alpha (TNF-α) and monocyte chemotactic protein 1
(MCP-1) that alter the tumor microenvironment through
autocrine and paracrine loops [49]. Many of these cytokines
were recently shown to act in autocrine but mostly in para-
crine fashion between tumor cells and the surrounding
microenvironment. These factors bind on the surface of
stromal cells to specific receptors and induce expression of
other factors that promote breast cancer cells aggressive-
ness, in this case in a paracrine manner [50].
Interestingly, our data also present a novel yet
expected conclusion [51], which suggest that BRCA1-IRIS
overexpression, which has been shown earlier to be
associated with metastasis and poor survival in invasive
ductal breast carcinoma is linked to uncoupling of the
AKT-FOXO3a signaling axis. This conclusion has been
reached based on the lack of FOXO3a in the nucleus in
more aggressive tumors, which is known to overexpress
BRCA1-IRIS and activated AKT. Thus it was predicted
that survivin expression would be positively correlated
with BRCA1-IRIS overexpression in aggressive and
drug-resistant tumors. This also can explain the fact
that paclitaxel failed to induce cell cycle arrest in
Blanchard et al. Breast Cancer Research  (2015) 17:5 Page 17 of 18BRCA1-IRIS-overexpressing cells, except after BRCA1-IRIS
silencing or inactivation since this would require FOXO3a
nuclear translocation to activate gene expression of cell
cycle inhibitors, such as p21 and p27, both were not
expressed in BRCA1-IRIS-overexpressing cells with
intrinsically or acquired paclitaxel resistance.
Conclusions
BRCA1-IRIS signaling in TNBC cells may significantly
reduce chemotherapeutic efficacy by promoting survival
of damaged cells, which is most likely a major reason for
the prevalent metastasis detected in TNBC patients
overexpressing BRCA1-IRIS [38]. BRCA1-IRIS inactivation
could be pursued as first-line therapy to combat TNBC
(as well as other subtypes) formation, progression and
their drug-resistant recurrence in order to reduce
TNBC-related mortalities.
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